Literature DB >> 1827217

Responses to NMDA receptor antagonists altered by epileptogenesis.

W Löscher, D Hönack.   

Abstract

Mesh:

Substances:

Year:  1991        PMID: 1827217     DOI: 10.1016/0165-6147(91)90496-f

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  8 in total

Review 1.  Discovery of antiepileptic drugs.

Authors:  Misty Smith; Karen S Wilcox; H Steve White
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

2.  Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy.

Authors:  H Potschka; E Friderichs; W Löscher
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 3.  Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.

Authors:  Melissa Barker-Haliski; H Steve White
Journal:  Neuropharmacology       Date:  2019-08-27       Impact factor: 5.250

Review 4.  Neuropsychopharmacological understanding for therapeutic application of morphinans.

Authors:  Eun-Joo Shin; Jau-Shyong Hong; Hyoung-Chun Kim
Journal:  Arch Pharm Res       Date:  2010-10-30       Impact factor: 4.946

Review 5.  New avenues for anti-epileptic drug discovery and development.

Authors:  Wolfgang Löscher; Henrik Klitgaard; Roy E Twyman; Dieter Schmidt
Journal:  Nat Rev Drug Discov       Date:  2013-09-20       Impact factor: 84.694

Review 6.  Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.

Authors:  Wolfgang Löscher
Journal:  Neurochem Res       Date:  2017-03-13       Impact factor: 3.996

Review 7.  The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?

Authors:  Wolfgang Löscher
Journal:  Neurochem Res       Date:  2016-08-08       Impact factor: 3.996

8.  The new KCNQ2 activator 4-Chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential.

Authors:  A Boehlen; M Schwake; R Dost; A Kunert; P Fidzinski; U Heinemann; C Gebhardt
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.